BioLine RX Ltd
TASE:BLRX
Intrinsic Value
The intrinsic value of one BLRX stock under the Base Case scenario is 34.64 ILS. Compared to the current market price of 2.3 ILS, BioLine RX Ltd is Undervalued by 93%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Fundamental Analysis

Revenue & Expenses Breakdown
BioLine RX Ltd
Balance Sheet Decomposition
BioLine RX Ltd
Current Assets | 27.1m |
Cash & Short-Term Investments | 19.6m |
Receivables | 4m |
Other Current Assets | 3.6m |
Non-Current Assets | 11.8m |
PP&E | 1.4m |
Intangibles | 10.4m |
Free Cash Flow Analysis
BioLine RX Ltd
USD | |
Free Cash Flow | USD |
Earnings Waterfall
BioLine RX Ltd
Revenue
|
28.9m
USD
|
Cost of Revenue
|
-9.3m
USD
|
Gross Profit
|
19.7m
USD
|
Operating Expenses
|
-39.1m
USD
|
Operating Income
|
-19.4m
USD
|
Other Expenses
|
10.2m
USD
|
Net Income
|
-9.2m
USD
|
BLRX Profitability Score
Profitability Due Diligence
BioLine RX Ltd's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
BioLine RX Ltd's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
BLRX Solvency Score
Solvency Due Diligence
BioLine RX Ltd's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
BioLine RX Ltd's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BLRX Price Targets Summary
BioLine RX Ltd
Dividends
Current shareholder yield for BLRX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?